Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.92.
Several equities analysts recently weighed in on MYGN shares. Bank of America dropped their price target on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research report on Friday, December 13th. UBS Group assumed coverage on Myriad Genetics in a report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price target for the company. Stephens restated an “equal weight” rating and set a $20.00 price objective on shares of Myriad Genetics in a research note on Thursday. Morgan Stanley cut their price objective on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a report on Monday, November 18th. Finally, Piper Sandler lowered their target price on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, November 11th.
Read Our Latest Analysis on Myriad Genetics
Institutional Inflows and Outflows
Myriad Genetics Trading Down 1.0 %
NASDAQ MYGN opened at $12.39 on Thursday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of $14.68 and a 200-day moving average price of $21.87. Myriad Genetics has a 52 week low of $12.17 and a 52 week high of $29.30. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -9.53 and a beta of 1.89.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Further Reading
- Five stocks we like better than Myriad Genetics
- P/E Ratio Calculation: How to Assess Stocks
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- 3 Ways To Invest In Coffee, Other Than Drinking It
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- How to Calculate Options Profits
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.